Matching-adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)

被引：0
|
作者：
Thieblemont, Catherine
Wang, Kaijun
Keeping, Sam
Zhang, Ina
Yang, Keri
Tang, Boxiong
Mohseninejad, Leyla
机构：
[1] Hop St Louis, Paris, France
[2] BeiGene USA Inc, San Mateo, CA USA
[3] BeiGene Switzerland GmbH, Basel, Switzerland
[4] PRECISIONheor, Vancouver, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19527
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] Comparative efficacy of zanubrutinib (ZANU) versus rituximab (RTX) in relapsed marginal zone lymphoma (MZL): Matching-adjusted indirect comparison (MAIC)
    Thieblemont, Catherine
    Wang, Kaijun
    Keeping, Sam
    Zhang, Ina
    Yang, Keri
    Tang, Boxiong
    Mohseninejad, Leyla
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] A matching-adjusted indirect comparison (MAIC) of the efficacy and safety of acalabrutinib (acala) versus zanubrutinib (zanu) in relapsed or refractory chronic lymphocytic leukemia (RR CLL)
    Staber, P.
    Kittai, A.
    Skarbnik, A.
    Miranda, M.
    Yong, A. S.
    Roos, J.
    Hettle, R.
    Palazuelos-Munoz, S.
    Shetty, V.
    Ghia, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 218 - 218
  • [3] A matching-adjusted indirect comparison (MAIC) of the efficacy and safety of acalabrutinib (acala) versus zanubrutinib (zanu) in relapsed or refractory chronic lymphocytic leukemia (RR CLL)
    Kittai, Adam
    Skarbnik, Alan
    Miranda, Miguel
    Yong, Alan S. M.
    Roos, Jack
    Hettle, Robert
    Palazuelos-Munoz, Sarah
    Shetty, Vikram
    Ghia, Paolo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Matching-Adjusted Indirect Comparison (MAIC) of efficacy and safety for tisagenlecleucel and mosunetuzumab in patients (pts) with Relapsed/Refractory (r/r) Follicular Lymphoma (FL)
    Dreyling, M.
    Fowler, N.
    Schuster, S.
    Yang, H.
    Xiang, C.
    Ramos, R.
    Maier, H.
    Jousseaume, E.
    Thieblemont, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 50 - 51
  • [5] Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL).
    Opat, Stephen
    Marcus, Robert
    Portell, Craig Anthony
    Reed, William
    Co, Melannie
    Huang, Jane
    Trotman, Judith
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] MATCHING-ADJUSTED INDIRECT COMPARISON OF EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS IBRUTINIB IN THE TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
    Telford, C.
    Kabadi, S.
    Abhyankar, S.
    Song, J.
    Signorovitch, J.
    Zhao, J.
    Yao, Z.
    VALUE IN HEALTH, 2019, 22 : S62 - S62
  • [7] Matching-Adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Ibrutinib in Relapsed/ Refractory Mantle Cell Lymphoma
    Gaitonde, Priyanka
    Cai, Ling
    de Miranda, Paulo
    Roos, Jack
    Rule, Simon
    Wang, Michael L.
    BLOOD, 2022, 140 : 3646 - 3647
  • [8] Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Maloney, David G.
    Kuruvilla, John
    Fox, Christopher P.
    Cartron, Guillaume
    Li, Daniel
    Hasskarl, Jens
    Bonner, Ashley
    Zhang, Yixie
    Liu, Fei Fei
    BLOOD, 2020, 136
  • [9] MAHOGANY: A Phase 3 trial of Zanubrutinib (ZANU) plus anti-CD20 antibodies vs Lenalidomide plus Rituximab (L plus R) in patients (pts) with Relapsed or Refractory (R/R) Follicular or Marginal Zone Lymphoma (FL or MZL)
    Buske, C.
    Nastoupil, L. J.
    Song, Y.
    Sehn, L.
    Sarkozy, C.
    Zinzani, P. L.
    Salar, A.
    Zhang, J.
    Zhang, W.
    Fustier, P.
    Delarue, R.
    Trotman, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 305 - 306
  • [10] COMPARATIVE EFFECTIVENESS OF TREATMENTS FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (R/R MCL), USING MATCHING ADJUSTED INDIRECT COMPARISON
    Tongbram, V
    Sengupta, N.
    Gaudig, M.
    Sidhu, M.
    Exuzides, A.
    Colby, C.
    Sanden, S., V
    McGovern, A.
    VALUE IN HEALTH, 2014, 17 (07) : A614 - A615
12345